The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
UGT1A1 genotype-based phase I study for recurrent and refractory gynecologic cancer patients treated with combination therapy of irinotecan and cisplatin (STB-06).
M. Takano
No relevant relationships to disclose
T. Goto
No relevant relationships to disclose
M. Miyamoto
No relevant relationships to disclose
A. Watanabe
No relevant relationships to disclose
M. Kato
No relevant relationships to disclose
K. Horie
No relevant relationships to disclose
H. Yokota
No relevant relationships to disclose
K. Kudoh
No relevant relationships to disclose
R. Konno
No relevant relationships to disclose
Y. Kikuchi
No relevant relationships to disclose